New Delhi, May 5 (IANS) Drug makers Cipla and Glenmark are recalling their products from the US market due to manufacturing issues.
In accordance with the latest Enforcement Report from the US Food and Drug Administration (USFDA), Cipla’s subsidiary in New Jersey is recalling 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution.
The reason for recalling the affected lot of Cipla products is “short fill”.
“Complaints received of less fill volume in respules and few drops of liquid observed in the intact pouch,” the US health regulator said.
The recalled drug is used to help control the symptoms of lung diseases, including asthma, chronic bronchitis and emphysema.
As mentioned by the USFDA, Glenmark is recalling 3,264 bottles of Diltiazem Hydrochloride extended-release capsules, which are used to treat high blood pressure.
The US-based arm of the company, Glenmark Pharmaceuticals initiated the nationwide recall of the drug due to “failed dissolution specifications”.
Meanwhile, drug maker Lupin has recalled products in the US market for manufacturing issues, according to the US health regulator.
As per the latest Enforcement Report by the USFDA, Lupin recalled 26,352 bottles of Rifampin Capsules (300 mg), an antibiotic medication in the US market.
–IANS
shs/svn
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
